

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/028604 A1

(51) International Patent Classification:

C07D 413/06 (2006.01) A61P 1/06 (2006.01)
C07D 413/12 (2006.01) A61P 1/10 (2006.01)
C07D 265/30 (2006.01) A61P 1/12 (2006.01)
A61K 31/5377 (2006.01) A61P 11/00 (2006.01)
A61K 31/5375 (2006.01) A61P 11/06 (2006.01)
A61P 1/00 (2006.01) A61P 11/08 (2006.01)
A61P 1/04 (2006.01) A61P 11/14 (2006.01)

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/GB2023/052050

(22) International Filing Date:

02 August 2023 (02.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2211232.0 02 August 2022 (02.08.2022) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**

[GB/GB]; Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(72) Inventors: **SWAIN, Nigel Alan**; c/o Heptares Therapeutics

Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **WHITEHURST, Benjamin**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **CONGREVE, Miles Stuart**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **BROWN, Giles Albert**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(74) Agent: **GILL JENNINGS & EVERY LLP**; The

Broadgate Tower, 20 Primrose Street, London EC2A 2ES (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES



(57) Abstract: The present invention relates to compounds of formula (I) as prostaglandin E2 receptor 4 (EP4) agonists for use in methods of treatment of gastrointestinal and pulmonary diseases or disorders. The present disclosure provides exemplary compounds and pharmacological data.

WO 2024/028604 A1